Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals

Nicholas Schwab (1) , Tilman Schneider-Hohendorf (1) , Béatrice Pignolet (2, 3) , Florence Bucciarelli (2, 3) , Lise Scandella (2, 3) , Jonathan Ciron (2) , Damien Biotti (2) , Christine Lebrun-Frenay (4) , Guillaume Mathey (5) , Pierre Clavelou (6) , Jean Pelletier (4) , Patrick Ostkamp (1) , Ingrid Meinl (7) , Susanne Windhagen (8) , Luisa Klotz (1) , Catharina Gross (1) , Sven Meuth (1) , Florian Deisenhammer (9) , David Brassat (2, 3) , Heinz Wiendl (1)

1 WWU - Westfälische Wilhelms-Universität Münster = University of Münster
2 Pôle Neurosciences [CHU Toulouse]
3 CPTP - Centre de Physiopathologie Toulouse Purpan
4 APHM - Assistance Publique - Hôpitaux de Marseille
5 CHU Nice - Centre Hospitalier Universitaire de Nice
6 CHU Gabriel Montpied [Clermont-Ferrand]
7 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
8 Clinics Osnabrück
9 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck

Low l-selectin (CD62L) on CD4+ T cells after cryopreservation has been introduced in 2013 as a risk biomarker for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment or HIV infection. The biomarker has been reproduced retrospectively in some international cohorts, but not in others, potentially because of its sensitivity to biomaterial quality, assay protocols, and the time point of testing. With regard to current approaches to PML risk reduction, natalizumab extended interval dosing is thought to improve immune surveillance and reduce PML risk, whereas clinical efficacy seems unaffected.

Domaines: Neurobiologie; Sciences du Vivant [q-bio]; Immunologie; Virologie

Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, Florence Bucciarelli, Lise Scandella, et al.. Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2019, 93 (12), pp.550-554. ⟨10.1212/WNL.0000000000008135⟩. ⟨hal-03001614⟩